BMMP
Based on 1 Customer Validation
BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer.
For research use only. We do not sell to patients.
- Purity: 99.85%
- CAS No.: 748785-70-8
- Formula: C13H11N3S2
- Molecular Weight:273.38
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Anti-Infection Compound Library
HY-L002
-
Epigenetics Compound Library
HY-L005
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Anti-Lung Cancer Compound Library
HY-L075
-
MCE Bioactive Compound Library
HY-L001V
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
BMMP (20 μM; 2 d) does not reduce the viability of 293T or M8166 cells[1].
BMMP (20 μM; 3 d) inhibits full-cycle HIV-1 replication across 293T and M8166 cells to 30% of control levels[1].
BMMP (20 μM) does not affect the release of HIV-1 virions from 293T cells[1].
BMMP (20 μM; 1 d) does not significantly alter the infectivity of HIV-1 virions produced by 293T cells[1].
BMMP (20 μM; 1 d) potently inhibits early-phase HIV-1 infectivity in M8166 cells to less than 10% of control levels[1].
BMMP (20 μM; 2 d) does not affect HIV-1 reverse transcription but suppresses nuclear localization and integration of viral DNA in 293T cells, reducing 2-LTR DNA to 60% and Alu-LTR DNA to 46% of control levels[1].
BMMP (20 μM; 1 d) destabilizes HIV-1 CA protein in infected HeLa cells[1].
BMMP (20 μM; 1 d) does not change the nuclear localization of hnRNP M but reduces HIV-1 CA protein levels in infected HeLa cells[1].
BMMP (20 μM; 1 d) inhibits early-phase HIV-1 infectivity in both control and hnRNP M-knockdown HeLa cells, indicating hnRNP M is not involved in BMMP's anti-HIV activity[1].
BMMP (0.1-100 μM; 2 d) at 0.1-50 μM does not reduce A549 cell viability, while 100 μM BMMP shows mild toxicity[1].
BMMP (0.1-100 μM; 24 h total incubation with TGF-β stimulation) inhibits TGF-β-induced migration of A549 cells in a concentration-dependent manner, with near-complete inhibition at 20 μM[1].
BMMP (20 μM; 1 h, 3 h, 6 h, or 1 d incubation with TGF-β stimulation) slightly reduces vimentin mRNA levels but does not inhibit TGF-β-induced EMT marker changes in A549 cells[1].
BMMP (20 μM; 1 d incubation with TGF-β stimulation) reduces TGF-β-induced increases in CD44s, CD44v8, and CD44v10 mRNA levels in A549 cells[1].
BMMP (20 μM; 1 d incubation with TGF-β stimulation) reduces TGF-β-induced CD44 mRNA expression in A549 cells via hnRNP M, as the effect is abolished in hnRNP M-knockdown cells[1].
BMMP (20 μM; up to 100 hours) inhibits replication of HIV-1 NL4-3 strain in human T-lymphoblastoid M8166 cells[2].
BMMP does not directly interact with HIV-1 Pr55Gag or CA protein in a cell-free surface plasmon resonance assay[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human kidney cell line 293T, human T-lymphoblastoid cell line M8166
-
Concentration:20 μM
-
Incubation Time:2 d
-
Result:Showed no significant toxicity to 293T or M8166 cells.
Maintained relative cell viability at ~100% compared to untreated controls.
-
Cell Line:HeLa cells infected with HIV-1
-
Concentration:20 μM
-
Incubation Time:1 d
-
Result:Destabilized the HIV-1 CA (p24) protein, reducing its detectable levels compared to untreated controls.
-
Cell Line:HeLa cells infected with HIV-1
-
Concentration:20 μM
-
Incubation Time:1 d
-
Result:Did not alter the nuclear localization of hnRNP M.
Reduced detectable p24 (CA) protein levels.
-
Cell Line:human lung carcinoma cell line A549
-
Concentration:0.1 μM; 0.5 μM; 1 μM; 5 μM; 20 μM; 50 μM; 100 μM
-
Incubation Time:2 d
-
Result:At 0.1-50 μM did not significantly reduce A549 cell viability (relative viability ~90-105% of control).
At 100 μM caused a slight reduction to ~85% of control.
-
Cell Line:TGF-β-stimulated human lung carcinoma cell line A549
-
Concentration:0.1 μM; 0.5 μM; 1 μM; 5 μM; 20 μM; 50 μM; 100 μM
-
Incubation Time:24 h total incubation with TGF-β stimulation
-
Result:Inhibited TGF-β-induced A549 cell migration in a concentration-dependent manner.
Reduced migration by ~50% at 0.5 μM.
Nearly completely inhibited migration at 20 μM.
Maintained significant inhibitory activity at 100 μM.
-
Cell Line:TGF-β-stimulated human lung carcinoma cell line A549
-
Concentration:20 μM
-
Incubation Time:1 h, 3 h, 6 h, or 1 d incubation with TGF-β stimulation
-
Result:Did not alter E-cadherin mRNA levels.
Slightly reduced vimentin mRNA levels at 1 d post-TGF-β stimulation.
Did not significantly reduce N-cadherin, snail, or fibronectin mRNA levels after 1 d of TGF-β stimulation.
-
Cell Line:TGF-β-stimulated human lung carcinoma cell line A549
-
Concentration:20 μM
-
Incubation Time:1 d incubation with TGF-β stimulation
-
Result:Reduced TGF-β-induced increases in CD44s, CD44v8, and CD44v10 mRNA levels in A549 cells.
-
Cell Line:TGF-β-stimulated human lung carcinoma cell line A549 (hnRNP M-knockdown)
-
Concentration:20 μM
-
Incubation Time:1 d incubation with TGF-β stimulation
-
Result:Did not reduce TGF-β-induced increases in CD44s, CD44v8, or CD44v10 mRNA levels in hnRNP M-knockdown A549 cells.
Chemical Information
-
CAS No. 748785-70-8
-
Appearance Solid
-
Molecular Weight 273.38
-
Formula C13H11N3S2
-
SMILES
CC1=NC(SCC2=NC3=C(S2)C=CC=C3)=NC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (365.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.14 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References
[1]. Kamo M, et al. Discovery of anti-cell migration activity of an anti-HIV heterocyclic compound by identification of its binding protein hnRNP M. Bioorg Chem. 2021;107:104627. [Content Brief]
[2]. Kamo M, et al. Synthesis of the biotinylated anti-HIV compound BMMP and the target identification study. Bioorg Med Chem Lett. 2016;26(1):43-45. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6579 mL | 18.2896 mL | 36.5791 mL | 91.4478 mL |
| 5 mM | 0.7316 mL | 3.6579 mL | 7.3158 mL | 18.2896 mL | |
| 10 mM | 0.3658 mL | 1.8290 mL | 3.6579 mL | 9.1448 mL | |
| 15 mM | 0.2439 mL | 1.2193 mL | 2.4386 mL | 6.0965 mL | |
| 20 mM | 0.1829 mL | 0.9145 mL | 1.8290 mL | 4.5724 mL | |
| 25 mM | 0.1463 mL | 0.7316 mL | 1.4632 mL | 3.6579 mL | |
| 30 mM | 0.1219 mL | 0.6097 mL | 1.2193 mL | 3.0483 mL | |
| 40 mM | 0.0914 mL | 0.4572 mL | 0.9145 mL | 2.2862 mL | |
| 50 mM | 0.0732 mL | 0.3658 mL | 0.7316 mL | 1.8290 mL | |
| 60 mM | 0.0610 mL | 0.3048 mL | 0.6097 mL | 1.5241 mL | |
| 80 mM | 0.0457 mL | 0.2286 mL | 0.4572 mL | 1.1431 mL | |
| 100 mM | 0.0366 mL | 0.1829 mL | 0.3658 mL | 0.9145 mL |
BMMP Related Classifications
HY-182514 Related Classifications
Powered by Bioz